Immunological and genetic analysis of 65 patients with a clinical suspicion of X linked hyper-IgM

• Published in: Molecular pathology 2003-10, Vol.56 (5), p.256-262
• Main Authors: Gilmour, K C, Walshe, D, Heath, S, Monaghan, G, Loughlin, S, Lester, T, Norbury, G, Cale, C M
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aging - immunology; Biological and medical sciences; Case studies; CD40 ligand; CD40 Ligand - blood; CD40 Ligand - genetics; CD40L; Cells, Cultured; Child; Child, Preschool; common variable immunodeficiency; CVID; Diagnosis; diagnostic strategy; DNA Mutational Analysis; FITC; fluorescein isothiocyanate; forward; Genetic aspects; Genetic Diseases, X-Linked - diagnosis; Genetic Diseases, X-Linked - genetics; Genetic Diseases, X-Linked - immunology; Humans; Hypergammaglobulinemia - diagnosis; Hypergammaglobulinemia - genetics; Hypergammaglobulinemia - immunology; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; immunodeficiency; Immunoglobulin M - blood; Immunoglobulins - biosynthesis; Immunological deficiency syndromes; Immunopathology; Infant; Medical sciences; Middle Aged; Original; Pathology, Molecular; Patient Selection; PCP; Pneumocystis carinii pneumonia; reverse; single strand conformation polymorphism; SSCP; TNFSF5; WAS; Wiskott-Aldrich syndrome; X linked hyper-IgM; X linked lymphoproliferative disease; XHIM; XLP
• ISSN: 1366-8714; 1472-4154
• DOI: 10.1136/mp.56.5.256

Background: X linked hyper-IgM (XHIM) is a primary immunodeficiency caused by mutations in the tumour necrosis factor superfamily 5 gene, TNFSF5, also known as the CD40 ligand (CD40L) gene. Patients often present with recurrent infections, and confirmation of a diagnosis of XHIM enables appropriate therapeutic interventions, including replacement immunoglobulin, antibiotics, and bone marrow transplantation. Aim: To review and optimise the institution’s diagnostic strategy for XHIM. Method: Samples from 65 boys were referred to this centre for further investigation of suspected XHIM. The results, which included a flow cytometric whole blood assay for CD40L expression followed by mutation analysis in selected patients, were reviewed. Results: Twenty one patients failed to express CD40L and TNFSF5 mutations were found in 20 of these patients. In contrast, no TNFSF5 mutations were found in 16 patients with weak expression of CD40L. Interestingly, one quarter of patients with confirmed XHIM who had TNFSF5 mutations had low concentrations of IgG, IgA, and IgM. Most of the remaining patients with XHIM had the classic pattern of normal or raised IgM with low concentrations of IgA and IgG. Conclusions: This study demonstrates the usefulness of the whole blood staining method as a rapid screen to select patients for subsequent TNFSF5 mutation analysis, and shows the benefits of a unified protein/genetic diagnostic strategy.